# From Breast to Orbit: A Case Report of Metastatic Breast Cancer With Orbital Involvement

**Authors:** Alhanouf M AlMansour, Nada A Almutairi, Nafisa Abdul Hafiez, Mohammad Alkaiyat

PMC · DOI: 10.7759/cureus.66927 · 2024-08-15

## TL;DR

A 40-year-old woman with breast cancer developed metastasis to the orbit and other organs, and was treated with radiation and hormonal therapy.

## Contribution

This case report highlights the rare occurrence of orbital metastasis from breast cancer and its management.

## Key findings

- The patient showed a positive response to orbital radiation therapy with a slight reduction in lesion size.
- Systemic treatment with hormonal therapy and palbociclib was initiated for metastatic breast cancer.
- Oncologists should be aware of ocular metastasis as its incidence increases.

## Abstract

The approach to manage breast cancer has undergone a significant transformation, leading to longer survival rates. However, there is still a rise in metastasis occurring in less common locations such as the orbit. We report the case of a 40-year-old female diagnosed with luminal A, left-side breast cancer, back in September 2020. She presented with de novo metastatic diseases to the liver, bone, lung, and orbit. She received palliative radiation therapy (RT) to the orbit at the dose of 25 Gray (Gy) in five fractions, and follow-up brain magnetic resonance imaging (MRI) indicated a positive response to treatment with a slight reduction in the size of the left infraorbital lesion. Systemic treatment was started with hormonal therapy fulvestrant and luteinizing hormone-releasing hormone (LHRH), leuprolide, accompanied by palbociclib. As the incidence of ocular metastasis from breast cancer increases, oncologists need to be vigilant about symptoms and use appropriate diagnostic techniques.

## Linked entities

- **Chemicals:** fulvestrant (PubChem CID 104741), leuprolide (PubChem CID 657181), palbociclib (PubChem CID 5330286)
- **Diseases:** breast cancer (MONDO:0004989)

## Full-text entities

- **Diseases:** left-side breast cancer (MESH:D000069584), metastasis (MESH:D009362), infraorbital lesion (MESH:D009059), Breast Cancer (MESH:D001943)
- **Chemicals:** fulvestrant (MESH:D000077267), palbociclib (MESH:C500026)

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11401625/full.md

---
Source: https://tomesphere.com/paper/PMC11401625